ProCE Banner Activity

Expanding the Spectrum of HER2 Positivity for Precision Breast Cancer Care: Clinical Implications of HER2-Low Status

Slideset Download

Review the latest evidence on HER2 testing, clinical implications of HER2-low status in advanced breast cancer, and mastering the safety profile of antibody-drug conjugates, including current guidelines and expert’s recommendations.

Released: December 08, 2022

Expiration: December 07, 2023

Share

Faculty

Nadia Harbeck

Nadia Harbeck, MD, PhD

Full Professor
Director
Breast Center, LMU University Hospital
Ludwig-Maximilians University
Munich, Germany

Komal Jhaveri

Komal Jhaveri, MD, FACP

Patricia and James Cayne Chair for Junior Faculty
Associate Attending Physician
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Heather McArthur

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca Pharmaceuticals

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Nadia Harbeck, MD, PhD

Full Professor
Director
Breast Center, LMU University Hospital
Ludwig-Maximilians University
Munich, Germany

Nadia Harbeck, MD, PhD: consultant: AstraZeneca, Daiichi Sankyo, Lilly, MDS, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz/Hexal, Seattle Genetics; fees for non-CME/CE services: AstraZeneca, Daiichi Sankyo, Lilly, MDS, Novartis, Pierre Fabre, Pfizer, Roche, Seattle Genetics, Nektar Therapeutics, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre, Prime Oncology, Puma Biotechnology, Roche, Samsung Bioepis, Sandoz, Sanofi, Seagen, Syndax, Synthon, Taiho Oncology, Takeda.

Komal Jhaveri, MD, FACP

Patricia and James Cayne Chair for Junior Faculty
Associate Attending Physician
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Komal Jhaveri, MD: consultant/advisor: AbbVie, AstraZeneca, Blueprint Medicine, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Genentech/Roche, Gilead, Jounce Therapeutics, Lilly/Loxo Oncology, Menarini/Stemline, Novartis, Olema, Pfizer, Seagen, Sun Pharma, Taiho Oncology; researcher: AstraZeneca, Context Therapeutics, Debio, Genentech/Roche, Gilead, Lilly/Loxo Oncology, Merck, Novartis, Pfizer, Puma, Zymeworks.

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Heather McArthur, MD, MPH: advisor: AstraZeneca, Bristol-Myers Squibb, Crown Bioscience, Daiichi Sankyo, Gilead Sciences, Immunomedics, Lilly, Merck, Pfizer, Puma Biotech, Seattle Genetics; researcher (paid to institution): Bristol-Myers Squibb, Merck.